common.study.topics.clinical

Treatment of Moderate to Severe Atopic Dermatitis

common.study.values.description

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Upadacitinib (ABT-494)

Upadacitinib is administered orally

Drug - Dupilumab

Dupilumab is administered as a subcutaneous (SC) injection

Drug - Placebo

Placebo pre-filled syringe is administered as subcutaneous (SC) injections

Drug - Placebo

Placebo tablets are administered orally

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

common.study.values.clinical-trial-id

NCT03738397

participant.views.study.view.id

bDkYna